ESPR 241220 2.00C (ESPR241220C2000) Stock Options, News & Quotes

US OptionsDetailed Quotes

ESPR241220C2000

Watchlist

0.20
-0.35-63.64%

15min DelayClose Dec 13 16:00 ET

0.31High0.15Low

Intraday

5D
Daily

News

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga16:06 ET
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $6
Moomoo News13:31 ET · Ratings
Esperion Therapeutics Price Target Maintained With a $6.00/Share by Needham
Dow Jones12:44 ET · Ratings
Express News | Esperion Enters Privately Negotiated Exchange And Subscription Agreements With Certain Holders Of 4.00% Convertible Senior Subordinated Notes Due 2025
BenzingaDec 13 06:01 ET
Esperion Announces $210M Convertible Debt Financing
Dow JonesDec 13 06:01 ET
Press Release: Esperion Announces $210 Million Convertible Debt Financing
Dow JonesDec 13 06:00 ET

Comments

AB84

21 hours ago

Hold

$Esperion Therapeutics (ESPR.US)$ 10 bagger one of these days

UnluckyDog

22 hours ago

$Esperion Therapeutics (ESPR.US)$
gone for good ? 😢

DazzlerAus

Dec 12 08:35

$Esperion Therapeutics (ESPR.US)$

Jaguar8

Dec 12 07:07

NEWS

$Esperion Therapeutics (ESPR.US)$
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...

Trytosaveabit

Dec 12 07:02

Update

$Esperion Therapeutics (ESPR.US)$ Reuters
1 min ago
Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel! Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments